<SEC-DOCUMENT>0000886163-15-000056.txt : 20150505
<SEC-HEADER>0000886163-15-000056.hdr.sgml : 20150505
<ACCEPTANCE-DATETIME>20150505081421
ACCESSION NUMBER:		0000886163-15-000056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150504
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150505
DATE AS OF CHANGE:		20150505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		15830511

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgndform8-kxclosingvikingi.htm
<DESCRIPTION>8-K-VIKINGIPO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>LGNDForm8-K-ClosingVikingIPO</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s1C816EFAFE57B678B15E218DF6F1FD3D"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:5px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): May 4, 2015</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92037</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:302px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1576354.4</font></div></div><hr style="page-break-after:always"><a name="s1C816EFAFE57B678B15E218DF6F1FD3D"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1576354.4</font></div></div><hr style="page-break-after:always"><a name="sDA26BBAE06D022369747218DF7159117"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01&#160;&#160;Other Events.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 5, 2015, Ligand Pharmaceuticals Incorporated (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;) partner Viking Therapeutics, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Viking</font><font style="font-family:inherit;font-size:10pt;">&#8221;) announced that it had closed its initial public offering (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Viking IPO</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share.  Viking granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the same price to cover over-allotments, if any.  The shares are trading on the Nasdaq Capital Market under the ticker symbol &#8220;VKTX&#8221;.  </font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the pricing of the Viking IPO, the Company purchased 1,125,000 shares of Viking common stock for an aggregate price of $9.0 million at the price offered to the public.  In addition, pursuant to the Master License Agreement, dated May 21, 2014 (as amended, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Master License Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) by and between the Company, Metabasis Therapeutics, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Metabasis</font><font style="font-family:inherit;font-size:10pt;">&#8221;), a wholly-owned subsidiary of the Company, and Viking, the Company received approximately 3.43 million shares of Viking common stock on the closing date of the Viking IPO, subject to adjustment in the event the underwriters exercise their option to purchase additional shares to cover over-allotments, if any.  As of the closing date, the Company owned an aggregate of 49.9% of Viking, based on the shares of outstanding Viking common stock at the closing of the Viking IPO.  </font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Viking IPO, the Company will make a cash payment to the holders of contingent value rights under the TR Beta Contingent Value Rights Agreement, dated January 27, 2010 (as amended, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">TR Beta CVR</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and the General Contingent Value Rights Agreement, dated January 27, 2010 (as amended, and together with the TR Beta CVR, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CVR Agreements</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Pursuant to the CVR Agreements, the Company estimates that the aggregate cash payment will be approximately $3.3 million, subject to adjustment in the event the underwriters exercise their option to purchase additional shares to cover over-allotments, if any. The payment is expected to be made on or about January 1, 2016.   </font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has issued a press release regarding the closing of the Viking IPO, a copy of which is filed as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 5, 2015.</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1576354.4</font></div></div><hr style="page-break-after:always"><a name="sDA26BBAE06D022369747218DF7159117"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="36%"></td><td width="14%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 5, 2015</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles Berkman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, General Counsel and Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1576354.4</font></div></div><hr style="page-break-after:always"><a name="sDA26BBAE06D022369747218DF7159117"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="2%"></td><td width="90%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 5, 2015.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1576354.4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>lgnd_vktxipox5415.htm
<DESCRIPTION>EXHIBIT 99.1VIKINGPRESSRELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>LGND_VKTXIPO_5415</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFD9D54C49CA3C14C954C2192E7660071"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:left;"><img src="lgndvktxipo5415image1.gif" style="height:38px;width:109px;"></div><div style="line-height:120%;text-align:left;text-indent:160px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:588px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="360px"></td><td width="228px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LHA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Todd Pettingill, Sr. Manager, Corp Dev and IR</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bruce Voss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@ligand.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 550-7500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(310) 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO (May 5, 2015) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) </font><font style="font-family:inherit;font-size:11pt;">partner Viking Therapeutics, Inc. (NASDAQ: VKTX) announced</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">that it had closed its initial public offering (the &#8220;Viking IPO&#8221;) of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share.  Viking granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the same price to cover over-allotments, if any. The shares are trading on the Nasdaq Capital Market under the ticker symbol &#8220;VKTX&#8221;. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In connection with the pricing of the Viking IPO, the Company purchased 1,125,000 shares of Viking common stock for an aggregate price of $9.0 million at the price offered to the public.  In addition, pursuant to the Master License Agreement, dated May 21, 2014 (as amended, the &#8220;Master License Agreement&#8221;) by and between the Company, Metabasis Therapeutics, Inc., a wholly-owned subsidiary of the Company, and Viking, the Company received 3,427,859 million shares of Viking common stock on closing of the Viking IPO, subject to adjustment in the event the underwriters exercise their option to purchase additional shares to cover over-allotments, if any.  As of the closing date, the Company owned an aggregate of 49.9% of Viking, based on the shares of outstanding Viking common stock at the closing of the Viking IPO.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As a result of the Viking IPO, the Company will make a cash payment to the holders of contingent value rights under the TR Beta Contingent Value Rights Agreement, dated January 27, 2010 (as amended, the &#8220;TR Beta CVR&#8221;) and the General Contingent Value Rights Agreement, dated January 27, 2010 (as amended, and together with the TR Beta CVR, the &#8220;CVR Agreements&#8221;).  Pursuant to the CVR Agreements, the Company estimates that the aggregate cash payment will be approximately $3.3 million, subject to adjustment in the event the underwriters exercise their option to purchase additional shares to cover over-allotments, if any.  The payment is expected to be made on or about January 1, 2016.   </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand will provide a summary of the accounting impact of this offering by June 30, 2015. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer&#8217;s disease, dyslipidemia, anemia, asthma and osteoporosis.  Ligand&#8217;s Captisol</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Ligand has established multiple alliances with the world's leading pharmaceutical companies including </font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1577423.4</font></div></div><hr style="page-break-after:always"><a name="sFD9D54C49CA3C14C954C2192E7660071"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly &amp; Co.  Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Follow Ligand on Twitter @Ligand_LGND.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. These statements include those related to Company&#8217;s ownership percentage in Viking; shares of Viking common stock to be received in the event the underwriters exercise their option to purchase additional shares to cover over-allotments, if any; the timing and amount of the payment to be made to holders of contingent value rights.  Actual events or results may differ from our expectations. For example, the cash payment to CVR holders is subject to adjustment based on Ligand&#8217;s reasonable expenses in connection with the Master License Agreement and Viking IPO and there can be no assurance that the final payment amount will be the same as the estimated amount. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via www.ligand.com as well as in Ligand's public current and periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SD\1577423.4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lgndvktxipo5415image1.gif
<TEXT>
begin 644 lgndvktxipo5415image1.gif
M1TE&.#EAQ@4+`O<```````````$!`>1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P
M'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'N1P'G%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q='%Q
M='%Q='%Q='%Q='%Q='%Q=')R=7)R=7-S=G1T=W=V>7IZ?']_@(:&AXN+C)"0
MD)&1D9*2DI.3DY24E)65E9:6EI>7EYB8F)>:FY>;G9:<GY:=H):>H9>>H9>?
MHIB@HYJ@HYZBHZ"CI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOKZ^SL
M[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OO[
M^_S\_/W]_?[^_O_______R'Y!`$`````+`````#&!0L"0`C^``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSYL(G.'/JW/G$IL^?0(,*'4JTJ-&C2),J7<JTJ=.G4)ORG$JUJM6J
M0Z]2U!JUJ]>O8,.*'4NVK-FS:-.J76OQJMNW<&U2/0AW;D&L;//JW<NWK]^_
M@`,+'DP8:MW#B''2M$N7IT&\C1T#2$R9:^'+F#-KWLRYL^?/H,56'@TY9FF"
M4R/O1$BZ]>'0L&/+GDV[MNW;N,NZWMU3;NG4K.=:'<B;=^[CR),K7\Z\N?/8
MQ5L7C<Y8-77*S[-KW\Z]N_?OX$?^7J^\>?SH\.C3JU_/OKW[R^83EX\O_[W]
M^QX9Z-_/O[___P#RA]^`!!:(''VO:88@8@8VZ*!``48HX804,O#@A1AFR-:"
M<2G(88<:AHA>A2262**(**:HXE$?NC5?BY:M*.-R)M9H(X`SYJCCCB?!.)R'
M/I[&XY"PW6CDC40FJ>22$`59'7Q./LGDE)<=:66%5&:II9)12I99E\!M*:9@
M5Y8IX)AHIHDBF#J]R*9B:N;XII=-&4G8G#'&:1*8>BKTIE!XNOFGF'/>B>>A
M<'J'Z*(@;N@D3(PNV&"D'^Y9*)"7:AEH6I1VBMV7GH:*(%A\@B1JI\V=&FI&
MFX+::I;^KT:EZJS%F47KK:4JE>M$N/;:IF>^!OLK0[$6ABBAF>HJ[++&+<7L
MLU%.UV5#T%:;4V#69CNL0,4:VNV2WP)UZTNX2FMM2=I>^].NDZ7K[FIHO2LO
MI8*RB>R@0:%J&+WK)DL6K37-F^!BY7X5K+@"OU4ONU.&2^ZQ:T$<\'6@Z6M:
MPKW)*JI4IXJ6\,+3;NDP2R-'[*],C2ZWZ,75ZF4Q4:OZ=2ZF^,)ZLDLW8UMS
MGZ@=^G"O4*Z<;Z3``DVSO2+GK)+2@^W,,W$EB]1Q:$)/7'5M&Q_-,)-1H[NU
MJR$_?1?3)#&:F\0L^^S<U4&3/637XB%=]-=/P^V1W53C;2K^VMKI[:C?*@)^
MM]P@PRAV<$[WZ#9M@F_$]W:-QZNVIHM[37C;81\^=N*6<H[;Y$N#KFCE?#W.
M->F6T]U7Y#9[7C;JT,'NN.BCNPZ8Z>#*_KKN!M,.-L:>ML1ZX3Z2/#S6O*N%
M.Y?)[[[\OF;_#;R\PC??V?$1/=^W]6=I_S;WG;\\=-:D3F^^D(K;;AOV3?K>
M'?L>P^^@_*F?[VY7]N>?,DKT-PV^1-Y[3O^\$L`=#7!P^IL9].[',?6%Y("W
M^U_VW,<=""[0@0:4(`(3N*SRJ4IF&IP@!F=C0<2%$#8E=$H!=91"A]B+@Y_2
M#;\PT\+'G-!;ETM?#8UUP][MD#W^/[1.BR["P`BNT(@YU*'J;A-$;AWQ0#TD
M(`63U$0G!DES/:OB4ZJH1<F-<&]39$X781;&[WV1(]'"HA6CZ,4DAF^)ZV.C
M"]F6JC*"<(S?:6+F#F='K3W*>&=$H1P?0K3CQ.QW;F1>(#6"1_<\46=]_$@C
M_S7(]A6R8N/R8QHIMTA&?I!*=/1?\`"9R,]5$H#B^TO+-/E'3I;RC3`TFA1#
MJ3Q?5:^3GYFD$&<H0^JQ\HI)PR488WD^J_$2?]JZY2OC*$S^91(I'"0>,8N9
M$ETF9)JQ7(DLTT9-;9ZR=-^<73+1:+0]\A";Q'1F,W^&SOS!LIV%W&3HUBG-
M(:H0GH?^W&6E?HG/CRG1G#[IIT`S)K6!%N^:K9SG,I%'3]\85%*\DB?F'HHQ
M=2[4HI&,'[,P2M&!B?"@WFPH(B7:RXXJK",`G:A)LZ50.!8THR.E937Q^5*0
MMC2E9PMG5M`94F"JL4#-FLDC22C3\<W***Y1UFX&5"N5`>R"#/JI5/])TMJ)
M=*I8S:I6M[JFJS)1IUP-JUC'2M;D@)4SUBRK6M?*UK::S*L,A:M;YTK7NMKU
MK1>M8UKORM>^^O6O/=VK!XL*V,(:]K"(5>HH<SFUQ#KVL9"-+,)6J;%G2?:R
MF,VL9I6Y4FQN]K.@#:UH:]I97X[VM*A-K6K%6=K%KO:UL(W^K6PEV=JESO:V
MN,VM;OLUSMWZ]K?`#:YPATO<%=F41?$IKG*7R]S#"A9]1)12<Z=+W>I*59?0
M#=/FX+7=;<W1H]8-KWC':Q_L:K>[=;E)/LG+WO:ZEZAR;8MTSPLU.JWQ5T-]
MKW[WRU].G960/]I*@.O[W_X:^,`(QEF!,4*:C\8WP1".L(1O6E51+GC"&,ZP
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M+?.:/NURM;/.'&M/HS=Z'G9M0,D'35MN^HJ??""T*#GG^L&SGK5V):`#*^N*
MD%JHV4;BM]DYO:3@^M#15BSPL&U/;4N:V^^F]IVEPV=8H_1=ME)VJ8^9[W2Q
M>Y_NKC`IM^U?85^(L-;>)CB1K6=[R]O9,14X%:-L;#/G]5X&/[:^57IQCG9[
MV>GFN,3^B=3(C`^;X!A'.3G'G3=B#_/CYF:YJCLN(SR:_-4T#[BI9UIQG)?<
MX8*\>:1AGE.A$WCD,]\Y'PM,]&9W&.'*:3J%X\W"'AM]Z"H/9LX]>?62;IWK
M/7\XU1TM=69^?8-CEU[6M;YV!H<=W6V/;ME1?/8V=MVJ<4=[VKV>=S?O>>![
M;WG=O>WR>O>=[X?'T',+K^Z[6_S7O08\TN.:^$D[?N&#[_?;39SYN#&\@3+W
M(>0K[^#`8S+C0#<[Z<.2^@S!7.$>9_:,1\]OJBK=D&=M/>,VOVC3%_OR`*9]
MJ.$N_)#'7M=1SSWC5>_[@O.^Z)TG;?$I1G?8:W3UP8\^#97^O_S=`Q_DSS?E
M]X,]_:`.MO9(OOG<L8[]4Z]?U+<7C.X/;G5(3S,OH3=R\^6N?9$?]_B3EVC]
MQWK=IW@7%H"!-GYP%GZ/UW[NYX!V!H$<5H"")X'PAX!RPG3QUR?SIW;[)U\*
M.$L#6'HA*'88Z&L,R'PGR%KAICD4B((6V&HCF'0;:'LQB'D=2(#OIV;<]X%F
M5(+[YH,"!H07^'^]1X0+N%[GE(*4)X2?EH.N]X*:!X7?-8/RUV4;IW_GYG_(
MUS`+)E#@\7EW9'PV:(2XIX"RYX&6Y7<`USI62(+EUX8^EG^B)RQ':(;0=X,@
MV%BSMV9L&(==6(8M"&Z`*(8\IX3^R69:4Q>(9_B&>O=,W)1.?UB(-?B(E?AL
ME%A#+`5VUR9YE^A]CBA]F=A@&I=FDSB*@RB*GTB(J)B%]]:*0K*"+.B$VX>$
M50B+E:9>JTAVN*B)GH9^A#=Z[T1[V9>*P\B(>4B+X$>,;K>+O-B+>GA?RCB$
M4OAGD`B`!C6+<HB-[2:`T6A,)N4\>'B*T'@>=VB*\#:-5VB(D3@OZ9A<D/*-
MSXB,Z^B'K+B-8T:.XQ$>5,A;YIB/U_5F``E8.RB"\CB0")F0=1.*0<>0"OF0
M$*DFMHA7#AF1%GF1N3.1W5.0&-F1'IE'U<AC(?F1)%F2/PAUC`6,)KF2+,DS
M$)=^6]C^DC(YDR[83GN80#29DSJY5>7HBCOYDT"I53V)CT%9E$9I5T,Y8$>Y
ME$RI6GW6E%`9E5(YE51I>/]HD%=9E5JYE7=5D<V8)Z68BUPYEF0IE+\(77"H
M+F6YEFPI-GMU&JQ6BFTYEW0Y)M8D7>2GED<GEFA9EW[YEX&S97B9EXFB<2;D
M78"9F(H9A9<WF'%YF'I)F*.RF)19F2GIE1,HEGL)7EFDDI;YF:!)D>IXDY&Y
MF9!9F)O9$_T8FJS9FOYXD+IH7Y(I@]N"%ZOIFKB9FPJ&ADH9C.=UF[H9G,(I
MCJ.Y<KUYFK(IC;`YG,S9G$^XG-1H?K2)F<Y9G=:9F=`9A-G^>9W<:9T<J8JR
MV)WB.9X1I9&>&)[DF9[J.9WHZ7SFN9X*P6+P"9'?*6WU69U@%F;SF67W66A,
MR)WY62/[Z63]:8GM.:`B$:!(@J!`5J"O^)_.J:!VPJ`ZYJ#&^9[7*:%'0J$U
M9J':6)P<&A$:.J$A6F(>RHG46:(&,:(DJJ(:=J()"*',R:(VXJ(D!J-?B:'6
M2:,":J,;AJ/\IZ,[RJ,GXJ,O*J/$N9TN2J048J0_BJ2>!Z4SRJ0XXJ1/*J2"
M.(Y66A)4FF-;"F)`2II*^I!9^14!>IFIAEM1A5B-!GICVG`@.B/[HU<O676]
M)7Y@27R>>9(^N8A:"F5ANH3T&('^YG,?V2ANZ-B`FQ@B]IBE1%F/6&II;TIN
MA"9&MU9+!QJ=^O,>/&6?*>IT4GIZGTJICU:!E&B-F8J=8`@Y*W6A<5J$@\JG
MJ9J$S(BH24E0>MJ-*-I:9C5J8NJ,^#>2!.*@O2B:MWJ<M@:LN_9K/%BKM_BJ
M6R2L3!6JQXJK?5BM;<I^?SIKPOAOS!J;D_J:HSIH,HJMF`:JYFI;B;BMRIF)
M-`B+W&J,D#JN_,B$Z9JGM'JOZ@JGC]JNQ8J#U9J:L3J&D=JL]%J>=>JJ!;.N
M^AH=_)JH`IN4:MBP!9NDT%I>FW=4F-BG[<B']W@PRPA2":NJBXJJ=XJPX:B/
MYI%R%QO^I"@9LB_[CN$:HV1(JC"TFR,;K2!KLVT6<<H:F$"XIS''CO'XL]=*
MM.>Y;G-8LR>GL=I9;BJ[CVS7LL\9JGX2L\?85#[K>(6:JTC[M'28K/ZTM>QJ
MIP>+G+,ZM/.FM0T)G,]ZLEB)M02#B.<'MUI(M>V15M*JK6FKL/BJ@F?K;Y@:
MMN#XM8@79V0KKQ,'?('ZMD:;.B"YMR2;L^[IMC0KMX>[L+5HM7-SMA&KN`#[
MN!GY='8XKX@FM#"IN5Q8MAG(M14+GJ`KD9)[M==XMS/;F98;MW1KNG@+1!3G
MN4O;N_1W@$R[NJS+C:(+J+M+J+?;:7?WN@EWO%,KO)\+O3+^F[P&2KTF.+MN
M"KP55'_-"[,#FR9:A+K>.GQ%R[TPV+@HZ[VLVG76&[VQ*[M"E[N#"[R&FXS:
MR[?[6Z_PZ[[Y*KW3.[XOU[^92\"PV[?7P[G9B\!R2F/Q:['S2[^CRK[(VZ^.
MJJMX!L`;:\"1&[@<G&O8.[K+:<$7C+[7*\!6J<`ZR,`BZ;D1[*DLS"-<Y,(?
M.\.6%\-@J\+W&\)K`[X>S+`.;)<:J,,WC,..B\0O'+Y'K,33ZKI,K*@C3,+:
M:\(9#+$GC,7?:\0?ZL3X,4E6#*Y!/"E%[,/55\7J*ZAC+,)1[(UK',9HR\.6
MNJHIC,&`.\2[NL;KZ\4Z:\-1Z[#^<\O%.:S'35M\YZC!G`>;]FN\6ORN4SR\
M'+S(3<S'A=R3AVS'34C)RVK&E:O)/N?'B=O('4O(!0S*DYNNERS*>'J0DJS&
MGES);9Q\)6B^_&O*N$NQ@RG!<KS`J)?&C(S"MOO(#R)K'"NN^=N]N'Q2=:S*
M*RS,2>S,;4O*A1O+O3J13AO(:0BKR:S,?CK!DBJ\K1S,WCR/U)S(TDR[.^NW
MM8O,VTR*RPS,C<C*ONS*T%R'G.S&KZS.^GK&[2R=60QL="K/<"S%]:R[^;P>
M1-?/I0G+FXK-:"S(H[S+FEK.VXO'QGK.`8W1MXS+_)S.!BW1ODG1#&W1+GO/
M4ZC1$4W^TET5M/W\T<5<MP?MKR#]QVS[SY/IOR;-LP4]K)S6SBW\TANI?K:L
MT^.LSRK=S$<=U$,MSHA,U$-YP!`=T@^=T^R<U!,MTC"]TT<;T^D!QNQ2J78W
MSVI;PDN=RO`LOUI]OO`8RI@L9TJZ;=VTQU'=Q3/=OES=R6G-GECMTDW-NW>-
MT]O)PM;'O'N=OF0]US@+G9B+U'5MLHCMR$7]H)&MR\C*V'G]TU-=V&*[OXM]
MQXU]?50=SYG=UQPHUEO]V8-\V:&KVG',VGZ-VEG]UV%8QJ1=VF7MGX<=VB,-
MVVDIVQ/KVHVGV:"HR,!M@`-=TL4MTY,MJH%]S,-]VW:-TK+^_*F^S=/0W<"U
MG<#9G<G)'9;2O=NZ_<[,+*O%'=[O^]BEW-W'':5C2LLT/=X$:]Z>O=S(S=N_
M=]UT;=^GK-^VVMV;',[:W-EX7=WO\U\`CK'KW=M<G>`RK,>IQ-8"'M;"_<TQ
M#=0T;-KH&N&_:M7OO:\$S>#_K;KT3.!;7,'5]L`8'KP/GK7TW;FWF\W!2EF;
MB]Z$S>%2#:^K/>'Y[=Y&O=W/3>+>;<'XUN'^?#K_J]":6<LZ?M77?(A+KN)`
M'N*$6]4E^\OP[=9CC.1K*KX>6N4VO;(9'>7QZMQL/+8SKN6<V<T^_N5HCIIF
MK>/NF+0MSLM43;F3W+40WN:YW.#^8EZ]>E[9E*WA@6ZW++[F!BO2,E[H-TOD
M:.[DWRV9?YY>;.[+]R?GAAYC\MWF&]W6.1[I<ZK=G,[EGK[G/3[JC^GH?<[7
MH=[!J#SF:WWFIB[IBG[EK![K?RO9M[KI9SWHM'[HCR[&3[W?-PWKMNXB5SSL
M4%[LIY[>J-C:KX[J_BWAT8[=@*C@`)WGRC[ID5?FRBZ0[%WMPO[LV@[(<RS?
M#UA^&[[K_=WMI%[JO7[LEY[A@HO6J%:UJ^[NZC[?\1[<J[;CXL[4[.[FWT[@
M4W[1Q<OLO)KNUZ[F]VZJJ<[G?X?;<S[@`2_PH/[N$F_NAKWB\-ZS_BZUXKWP
MT_WD"E_^Z?0N\FJMYY:.\1^_[XQ.?1^.YP./[`R?[]S-WY]L/QO?\`#OTW<.
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M;_/Q7__YB(3&_LP6;__\+V8I=NL``4#@0(("GQQ$F/!)088-'3Z$&%'B1(H5
M+5[$F%'C1HX=/7X$&5+D2)(E39Y$F5+E2I8M7;Z$&5/F3)HU;=[$F1.B0IX]
M??X$JE`G0:`BBPY%FE3I4J9-G3Z%&E7J5*I5K5[%FE7KUJ!=O7Y-^K/@UX0.
MCVY%FU;M6K9MW;Z%&U?N7+IU[9XDFU?O0:1BQ^[ER]#O7<*%#1]&G%CQ8L:-
M'3^>"UART*&#B4Y>^+<G9,Z=/7_^!AU:]&C2I4V7Q)Q:J$Z?9GDVM#RP]6G:
MM6W?QIU;]V[>O2.J!IX9YVS8KUVOUFS<]W+FS9T_AQY=^O2.P56SWGR\;''E
MR;=3!Q]>_'CRY<V?KVH]-?;NWO4^)(Y>_GSZ]>W?QQ]>/6;VR`7OE2@^]ZS+
MKT`##T0P00471&F_R?K[[C_`=LH.``?)8C!##3?DL$,/H;MPPIP$O,P_@TB4
M;;,0W_NP11=?A#%&&=M:D<41*QR0N_9.?*U&&V<$,D@AAR2RR)!\Q!#""%,T
MD<DFQ4(R+R.GI+)**Z_\,$JO^B(1QQ)-]$M+L+`DLTPSST3S.3$IX])++[_\
M;K`UNTK^LTX[[\0SS\3FC.U&%#<ZRT(^^]2S4$,/1331R@;=T<\_+6+324:7
M5+122R_%-%.,)FURT4`IHE-"3A'2M%133T45T5%)=4K*`0GE<57A4J6U5EMO
M!5+665N],$!==\4U6&&');8^7=,#KJ)?@2VV66>?A7:W8[5*<M-?H\4V6VVW
MY6S:SY;E-EQQQR67+6\]`[=<===EMUTE&0TM77?GI;=>>T$ZMS-Y[^6W7W__
MS;?;:_\EN&"#RPT8LGT/9KAAAX--^+&%'X:6`8LOQMABBC=^-F+')N88U8Q'
M)KGDDD-&N52/&P,YY4I-ACEFF35VN>9"5V:L99L+G;EGGT?^WCGH-'%>3&>A
MZ_PY::49.+II*XE6S&BGRURZ:I^GQGI(J/<<..LTK09[9J_'AG%KQ*0FN\BP
MUXXY;;<Y-/LPM-\&DFV[3Z8[[P3C-FQNO6&\._",_R8</[X+\[OP#P5GG&G%
M'T?O<,(2AUS#QAFO///Q)+^+<LT5O%SPST>7CG.[/"?=P-`#3[UUYDRO"W77
M[UN=]=EOQPUVNF3'?;[:[^X]^--TCZQKX1?\W>[CEX]7UN:)9YZZY->.OGJ!
M5WW>>>L/G#[L[;\O6OMOC0??ON[!+C]]Q,5'EWSU?3]_Z??G+QY[T'BGO[GX
ME<Z_?[>@CPO^_->;_25M@`=$"P#^X2)`!.JF@#UK8`2OHL"W,%""MWF@S"ZX
MP:A0\'_NXZ!T,FBR$):0*1ZD$0A-^)P1#FZ%+_34J+)G/QA.IX4UQ.%PV*<O
M%>90?^?S81!K@D)S]5"($UF3)SR!EL;Q$%[N\E&JHB05(J[%@AM<5J2JE$4`
M#8N+=^)B8&+(J1G*$(R]ZDT8^?,B-89H>/NA2ANUJ#4Y?DHF553+%;/$)]/4
MT4%[\^.<KC?%L`3252XR9!=A@L>TZ'%#-!QD(MTH'TDR\BE/M$DE'Y0A3:ZG
M)9;DBA&)M$.N=5),X#&E&M?'QYFD,ED%<B6!4@)*:HE22+1L2BPGM1Q=&G)W
MNW1)+^'^2$EA_A$UI%28+8.$RT(6$YBV<:8F%_C,!D43C>*QYHI&PLP)*C-7
MR`Q@-L&93'&:,H68/&8YKQD==4;Q(]RTBB,Y.<XBMI.>9[-G+*U(S2/ELT;.
M\2<A`77/\,&3/@9=9$#EB16%"C.!_*Q.0]TI+8D*U%J0=")!EZG1>%;TBY/S
M:#%KB4Z.A-2BM#'I*2^"T*DL=$$LG65*/RH7F4:3H1!=:4U/.AJ=KDE9',4G
M3,\CU'3VU*7O,JHK.TI22"5UIQEUZE-%1<;[>7-&1#5*5&?Z4*TZ,XXX_4U7
MI<HRL?J40AB-I!FOA-5WEG6K-W6K2#L(5NW$]9_DM*N6X`/^5+E9549L+6E>
MW]I2P<KUDG1]56&-65#%JA1.B,V97V,$6(TT-HM+M:PN#\O4J69VDJ7TK%XE
M!5G&HG5*E,UI:"5[$]5J-I>(;2V2@AI;T:)6*4<%I&EYU<O`&A8JM%7J"<$*
MW+%.D[@-+2-5U\I7UG;R):G\;3Y[:T_A,O6XHOWE=9%;5=M2I[MG#:2CPKM;
MZ`[1MV,4Y&BUJ\WZ2;>SGDTN:3>JVV;*\;5^).]X[VO.^K)2DEGUJG'/V\^X
MQI>S1OJNCL+XU3;N=[#(JF1_DQI,UYXSN`F-JH$'1:8$/Q:W%%[P4CZL0U^B
M-Z4DEF8]4RQ>F6J8E<NE+XHOV\C^$$LXO9W3KXP]*N(5A[+'MVTQ=YE;MB&#
M>,8J7BU+-APU_+)8H7--)%>CS&")NOC&3ROR)X]<P2T[>9T2:["7V]G-'&.V
MR5FILI!C3,<UTZ3+X4RR2M@KFC`WUY]2KK.9[;M/]XZOPR#*LISCC.815U8]
MM<FSFZF+Y!I3><]<5J>5S0ICM2+UP-D--%ZNDYM&*[J<`E:EHT/=7FM*VK%8
M;G-,!DWC3)MDDVE\,(9MBNE85S?1L2NUFBN]Q587===][;6OY^B;6AO9H3@>
M]6:3W;<`^SG8CWPV@5.-ZVFK&E:O*S2H!GRZ3MNZV\"N</O^K*9HXZO<>)9O
MF=XLZPO^SS;;YOXVD_6I:^6B^M>>OG=I+UVG=X>UW?+N=T3C'=GR.KO:?SVW
MP.L-YH-C*>!UC3!>5[V26Z=UR@;/=Y$HFW`^+SQ/#U?PQ2V><3L76^(EQKC'
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M'[N,/S^EX__[\,-__3/?>^K)/GO=S[?^`*:]XN,]\)L__+L__AM`=CM`\OL_
M6FO`#N&^`F0^"5RY!80Z"AP[Z4.Z]+N^`)Q`"WRI]G,_V;JZ!ZQ`$\0[#$RY
M[U-`%60[$&0T%YPG&,P(&K2P_AN:]N/`X)/!&LR_E^O!&T1!#3F](82S(/0_
M)-0V&P1"#P1`)C2\B7([(V20(E3^PAA,0#V!J1T4-2<4/RIDP"MD-1$T#RL4
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M'$NA=#6DI$F[!$NEE$-B;,NL+`_@.SNY7+9!K$NVM$?`I"GM^TK]4[VNT\M&
M5$R<'$P@*S.Q/$RT'"B^7,R`;$P!],M<Y$QL=,M$O,R6_"_^P\Q,S4Q+UKQ%
MQ-3'T?0^UX0TO.2-'2RXQ(PXS%S-E-Q*2X/-N_S-;Y1-5+1-BBK.0#RV"^0M
MWNQ-MQQ.':--Y4S.[)M,;RO-,CS.37Q.65K$[F3*6@Q-Y#3+SYS-\73,:SS!
MZV1.\)0,YW1/W]Q.XBS/\'Q-]82\ZIP.+HS/5Z++_@S&["2UJAP^]NQ(]`3-
MZ;1)`;5(`%4D0GNRHY1/_53-X!Q*!&6G^=2RZ)Q"!8U-!SVD_VQ.E+10X630
M/R304$S1$J10X(S,R1I($'U/$DW-VIS0$P6U%84X'#W0%RU''D6E?911A/S.
M&N5'#+U0_"S*^K1/!%12T03276S^4>X<TBVA1JL[2R15.PW52K4TSQXM47S4
M4AAMT2H=DROENA_UT"6,4IX,T[ULTX7441&=4\/Y13,-%3=MTORJ4_'TT3=Z
MR"^USCXE,R[UNRC%4SN"3PXUS1LU4"%<4ZM\5#F-U$5]4S(%TD1ME`J=TDPB
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M_-I1?-J@-5S2+%O%=;JI_=FC]5O+)=B(%=S`[=+([5C.)<+^PIW<5,7;O%5;
MTNW0M=U9Q$580;6QP0U2SZ3=^\#:K&7=]G3=^_39SV5<"9W+\SQ=PK7=VS46
MV)6VU=5<I=/$X67;XE5:T%5%)D7>;L5<>ZW:[/77W5W<W.U9V55=ZLT=TR5?
M@.1>?5W9]/54587>M7S?:+W>#`U4Y87,YA73D[7?:67/N/3=^)7<WIU!+Q5?
M\BC@6UW?U!U9Z?5?^&T[)\7?Y#-?T95,!6[*``W>M+W=!N[+I;O?ATW"[7U@
M6`1?X:7@UY5>2!7@S=W?':4Y!P;A;TI@([VE`Q9;`%[>^<57$CS5%JY8_OK?
MWQTED_TT]K-AMQUA[4UA/15BN#W^8=W-30B.X:LB0W&\6/9E4RS-W"F^XB6.
ME<)LVGB5XB:NX8#55$I1X?-%X=/4237F4R\N5S#.UED+8L^]7`$]XVH!7"P^
MUC1MXPS.RPB.71SNPERKXWP-8</-XU<S83[^8B`&7BZ&W'[UX/#=MOQTXUV]
MSD7>-`1FU$OF7QVV9!ZV5C\NY#'K7#).Y!7>6DY^4'H%Y`8-M[*,Y5,6Y%`V
MY3<.J.AMVYO-5%?VR1M^XAZ>MPOV7AA&9&'.96(&UT,&9CV.9%6.YF=^9;F5
MX]#-)B2&XQV.RE*FX75,,V>FYC.EY?D=YV">YA*6Y2(VYEM.95)6-DBVYI[B
MY7-6U%?^9>7$M><9+>=EUN8^2V=XQC:\;3;UQ2]15N9]YF<ESN<D56AHQF4M
M#FAVGNC#0]]:7C3>K5&$;M^']L\_YNA1]6ARQN<7?D*=^N=CQN1M5M%GMD:+
M'>.1SE.09NE8E>D?&60Z=N&R2FEW%F>87F!.[F.+CNF;OC83K661-NHW^=`S
MCN-D=F@[AEH+?N0\MFE)#N"EME*:;NB(UNJ9-F@\_>%NYFJ55E>SWF('E52H
M=MBOOF>D#FFE=NMABVKW?.G%JNA>'NA,UM0LQNK1G>MZE-H,#NR/;NK^'&J@
M9FBT[F"?3NCN7&>VEM_"/NK!#FG*9LF<?LZKEFK-_FN)K&G^KP1/T9;F_,5L
M-#YLQE[CTU[HU#[,`I7LDP[MQHUKC8;*S51MOF5MU(;K;=YM=';MC/3KS@[K
MKI97X^[HL6QELC[KWQ8CKW9LV5;6KEIL*Q[NV,[AV=[CW);9@V1AYCYNYW[N
MDH[NU4YJW`;EN@ZM1BUMR]9N#7[OY88OZ<9N2A5O9BEN[K[N3#9OB?9LR_I>
MX@[N]I[D\V[-S.IM`3=8UNYGY*9.1S[P@:UNP>IOO9YP`M?DVJ;O`LMO@?Y@
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M%Z=`[OJS9WNT#^<DE^>VEWNWOV]&G_N[I_NZ7R.\Y_M[UWM&[OO`9_>_AVC!
M-WRB)_S*/OS%]_;$[Q3&AWQU3_S(IWQ_O^_*QWR<!_',Y_P_@G?KS@=]AI?I
MT"?]B1_GTD?]C^_KU&=]F`?0UH?]H5?NV*=]K0>NVL?]NV?5W.?]R-^QW@=^
+W+_ZX"=^I@@(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
